Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,808.82
-23.6581-1.29%
Number of Gainers:- -
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,843.64
Open:1,841.43
Low:1,804.81
Close:1,832.47
Volume:5.42M
Turnover:771.08M
Market Cap:466.42B
Float Cap:451.90B

Loading ...

Gilead extends Arcellx tender offer deadline to April 24

Reuters
·
Apr 02

Gilead Extends Tender Offer to Acquire Arcellx

THOMSON REUTERS
·
Apr 02

Gilead - Tender Offer Expiration Extended to 5:00 P.m. Et on April 24, 2026

THOMSON REUTERS
·
Apr 02

Gilead - Offer Price $115 per Share Plus $5 CVR Payable March 31, 2030, IF Sales Milestone Met

THOMSON REUTERS
·
Apr 02

Gilead Sciences Inc Stock (GILD) Moved Up by 3.03% on Apr 1: Facts Behind the Movement

TradingKey
·
Apr 01

Gilead Sciences Inc Stock (GILD) Moved Up by 3.62% on Mar 31: A Full Analysis

TradingKey
·
Mar 31

Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves

TIPRANKS
·
Mar 31

Galapagos, Gilead enter pact to collaborate on T cell engager therapies

TIPRANKS
·
Mar 31

BRIEF-Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition

Reuters
·
Mar 31

Galapagos, Gilead sign deal tied to Ouro acquisition for T cell engager program

Reuters
·
Mar 31

Galapagos Nv - Enters Binding Agreement With Gilead on Ouro Medicines Acquisition

THOMSON REUTERS
·
Mar 31

Galapagos Nv - to Fund 50% of $1.675 Bln Upfront and 50% of Milestone Payments for Ouro Deal

THOMSON REUTERS
·
Mar 31

Galapagos Nv - May Spend $500 Mln Independently, Including up to $150 Mln for Share Repurchases or Dividends

THOMSON REUTERS
·
Mar 31

Galapagos Nv - Galapagos and Gilead Enter Into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

THOMSON REUTERS
·
Mar 31

Galapagos Nv - to Buy Ouro's Operational Assets Including Facilities and Personnel

THOMSON REUTERS
·
Mar 31

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 31

Novartis Says Drug Improves Kidney Function in Patients With Berger's Disease

MT Newswires Live
·
Mar 30

Novartis announces two-year results from Phase III APPLAUSE-IgAN study

TIPRANKS
·
Mar 30

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 28

Novartis to buy biotech company Excellergy for up to $2B

TIPRANKS
·
Mar 27